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Mammalian retromers play a critical role in protein trans-membrane sorting from
endosome to the trans-Golgi network (TGN). Recently, retromer alterations have been
related to the onset of Parkinson’s Disease (PD) since the variant p.Asp620Asn in
VPS35 (Vacuolar Protein Sorting 35) was identified as a cause of late onset PD. This
variant causes a primary defect in endosomal trafficking and retromers formation.
Other mutations in VPS genes have been reported in both sporadic and familial
PD. These mutations are less defined. Understanding the specific prevalence of all
VPS gene mutations is key to understand the relevance of retromers impairment
in the onset of PD. A number of PD-related mutations despite affecting different
biochemical systems (autophagy, mitophagy, proteasome, endosomes, protein folding),
all converge in producing an impairment in cell clearance. This may explain how
genetic predispositions to PD may derive from slightly deleterious VPS mutations when
combined with environmental agents overwhelming the clearance of the cell. This
manuscript reviews genetic data produced in the last 5 years to re-define the actual
prevalence of VPS gene mutations in the onset of PD. The prevalence of p.Asp620Asn
mutation in VPS35 is 0.286 of familial PD. This increases up to 0.548 when considering
mutations affecting all VPS genes. This configures mutations in VPS genes as the second
most frequent autosomal dominant PD genotype. This high prevalence, joined with
increased awareness of the role played by retromers in the neurobiology of PD, suggests
environmentally-induced VPS alterations as crucial in the genesis of PD.
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INTRODUCTION
Mammalian retromer is a protein complex composed of three vacuolar protein sorting (VPS) 26,
29, and 35, with an important role in trafficking trans-membrane receptors toward the endosome
compartment (Nothwehr et al., 1999; Seaman, 2012).
In 2011, two different studies carried out in selected kindreds affected by Parkinson’s
disease (PD) by using next-generation sequencing (NGS) identified an aspartic-acid-to-asparagine
Gambardella et al. VPS Mutations, Retromers and PD
mutation within VPS35 gene (p.Asp620Asn) (Vilariño-Güell
et al., 2011; Zimprich et al., 2011). In silico analysis showed
that amino acid Asp620 within VPS35 gene is highly conserved
from yeast to humans. Moreover, studies based on molecular
dynamics simulations predict that the variant p.Asp620Asn, is
a deleterious substitution since it reduces salt bridges, which in
turn produce an increase in protein flexibility (Vilariño-Güell
et al., 2011; Zimprich et al., 2011).
As reported by Trinh et al. (2014), the cumulative
incidence of VPS35 p.Asp620Asn has a lower quartile
when considering age at onset <45 years and an upper
quartile when considering age at onset >59 years. This
mutation has a high but incomplete penetrance. Clinically,
unaffected carriers have been reported. Four carriers between
49 and 67 years at the time of exam (Vilariño-Güell et al.,
2011), and three carriers younger than 60 years (Zimprich
et al., 2011) have been described so far. It still remains
to be established whether these mutations are really non-
penetrant or these patients were evaluated at a pre-symptomatic
stage.
Incomplete penetrance would be consistent with slight
consequences produced by this mutation, which minimally
affects the association with VPS29 and VPS26 to constitute
the whole retromer complex. In fact, this mutation of VPS35
produces a protein with abnormally flexibility, but it remains
correctly folded and binds VPS29 and VPS26a with the same
affinity of wild-type VPS35 (Follett et al., 2014).
Conversely, in the hypothesis that this mutation possesses
almost full penetrance, this may produce severe alterations
in endosomal morphology and trafficking. In line with
this, p.Asp620Asn causes retromer misplacement toward a
perinuclear area, as witnessed by enlarged stagnant perinuclear
endosomes described in a PD patient (Follett et al., 2014; Tsika
et al., 2014).
In addition, the mutation p.Asp620Asn despite not
altering the binding of VPS35 with VPS29 and VPS26a, it
does impair the binding of VPS35 with FAM21-containing
WASH complex, which mediates the production of branched
actin networks on the surface of the endosomal membrane
(McGough et al., 2014; Zavodszky et al., 2014; Tsuyoshi
and Yuzuru, 2015). This alters the trafficking of cathepsin
D, which is responsible for the degradation of a number
of proteins including α-synuclein (McGlinchey and Lee,
2015).
However, the molecular mechanisms which lead from
this VPS mutation to neurodegeneration remain unclear.
Recent studies demonstrate that all VPS35 mutations in
PD cause mitochondrial fragmentation and neuronal death
(Tsika et al., 2014; Zavodszky et al., 2014). These effects,
linking VPS35 to mitochondrial homeostasis, reveal a novel
mechanism of disease. This is in line with findings showing
that autophagy is impaired in cells expressing VPS35 mutations.
The impairment of autophagy and mitochondrial turnover
in association with altered kinetics of exosomes may depend
on abnormal trafficking of the autophagy protein ATG9A
which indeed occurs in this PD genotype (Haelterman et al.,
2014).
PREVALENCE OF VPS35 VARIANTS IN
FAMILIAL AND SPORADIC PD PATIENTS
Several analysis have been carried out in PD patients in order to
establish the contribution of VPS35mutations to the onset of PD.
From 2011, 15 case-control studies worldwide analyzed a total
21,824 PD patients. Some of these studies considered familial
(F)- and/or sporadic (S)-PD as independent populations, while
others considered S-PD and F-PD as mixed population (M-PD).
In these latter studies the occurrence/absence of the disease was
investigated only in the families of the carrier. Based on these
studies, an accurate re-appraisal of literature allows to re-define
the prevalence of VPS mutations in M-PD, S-PD, and F-PD
(Table 1; Vilariño-Güell et al., 2011; Zimprich et al., 2011; Ando
et al., 2012; Deng et al., 2012; Guella et al., 2012; Guo et al., 2012;
Kumar et al., 2012; Lesage et al., 2012; Sharma et al., 2012; Sheerin
et al., 2012; Zhang et al., 2012; Chen et al., 2013; Sudhaman et al.,
2013; Blanckenberg et al., 2014; Gagliardi et al., 2014).
M-PD
Total prevalence of VPS35 mutations in M-PD derive mostly
from the mutation p.Asp620Asn and rarely from other
mutations. The frequent p.Asp620Asn mutation has been
genotyped in a total of 21,824 M-PD, and it was detected in
25 patients (prevalence of 0.115%, Table 1). Among these, only
21 patients were affected by PD at the time of genetic test
(Vilariño-Güell et al., 2011; Zimprich et al., 2011; Sharma et al.,
2012).
On the other hand, data on rare variants are limited to genetic
studies which considered the whole VPS35 gene sequence. The
most important variants being detected are p.Pro316Ser (1/4515,
M-PD) (Vilariño-Güell et al., 2011), p.Arg524Trp (1/860 S-PD)
and p.Ile241Met (1/860, F-PD) (Chen et al., 2013), p.Leu774Met
(2/860PD and 6/8870) and p.Gly51Ser (3/8870) (Zimprich et al.,
2011; Sharma et al., 2012). Further analyses of these variants are
strongly required in order to understand their contribution to
the onset of PD. In fact, while p.Arg524Trp and p.Ile241Met
are predicted to be deleterious by molecular dynamics analyses,
the pathogenic role of p.Pro316Ser remains uncertain. Further
studies are required to ascertain the pathogenic effects of the
mutation p.Leu774Met (which owns a limited impact on protein
stability), while the significance of the mutation p.Gly51Ser
remains unclear.
Assuming pathological effects for all these VPS35 rare
variants, their prevalence occurs in up to 0.105% (15/14247)
of M-PD (Table 1). When adding the prevalence of these rare
VPS35 mutations to the most common p.Asp620Asn mutation
(0.115%), the overall prevalence of VPS35 variants reaches
0.220% which potentially contributes to M-PD.
F-PD and S-PD
Data on the specific contribution of VPS35 variants in F-PD and
S-PD can be obtained from case-control studies which consider
F-PD or S-PD as distinct populations (Ando et al., 2012; Deng
et al., 2012; Guella et al., 2012; Guo et al., 2012; Kumar et al.,
2012; Lesage et al., 2012; Sheerin et al., 2012; Zhang et al., 2012;
Chen et al., 2013; Sudhaman et al., 2013; Blanckenberg et al.,
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TABLE 1 | Prevalence of mutations in VPS genes.
Gene Variant References Patients Analyzed
M-PD F-PD S-PD
VPS35 Asp620Asn Sharma et al., 2012 8870 (7) nr (5) nr (2)
Vilariño-Güell et al.,
2011
4432 (5) nr (4) nr (1)
Zimprich et al., 2011 1348 (4) nr (4) nr (0)
Ando et al., 2012 733 (4) 300 (3) 433 (1)
Deng et al., 2012 202 (0) 72 (0) 130 (0)
Chen et al., 2013 609 (0) 37 (0) 572 (0)
Guella et al., 2012 475 (0) 475 (0) nr
Guo et al., 2012 1038 (0) 27 (0) 1011 (0)
Kumar et al., 2012 1774 (1) 539 (1) 1235 (0)
Sheerin et al., 2012 597 (1) 335 (1) 262 (0)
Sudhaman et al., 2013 320 (0) 69 (0) 251 (0)
Lesage et al., 2012 246 (3) 246 (3) nr
Blanckenberg et al.,
2014
418 (0) 418 (0) nr
Zhang et al., 2012 512 (0) 32 (0) 480 (0)
Gagliardi et al., 2014 250 (0) 250 (0) nr
Tot 21,824 (25) 2800 (8) 4374 (1)
% 0.115 0.286 0.023
Leu774Met Sharma et al., 2012 8870 (6) nr nr
Zimprich et al., 2011 862 (2) nr nr
Pro316Ser Vilariño-Güell et al.,
2011
4515 (1) nr (1) nr (0)
Arg524Trp Zimprich et al., 2011 862 (1) nr nr
Ile241Met Zimprich et al., 2011 862 (1) nr nr
Met57Ile Zimprich et al., 2011 862 (1) nr nr
Gly51Ser Sharma et al., 2012 8870 (3) nr na
Tot 14,247 (15)
% 0.105
VPS26a Lys93Glu Shannon et al., 2014 1906 (0) nr nr
Lys93Glu Gustavsson et al.,
2015
396 (1) nr nr
Met112Ile Koschmidder et al.,
2014
245 nr nr
Met112Val Gustavsson et al.,
2015
396 (1) nr nr
Lys297X Gustavsson et al.,
2015
396 (1) nr nr
Pro316Ser Koschmidder et al.,
2014
245 (0) nr nr
VPS29 Asn72His Shannon et al., 2014 1906 (1) nr nr
Tot 2547 (4)
% 0.157
Variants of VPS26a, 29 and 35 are shown. For each variant the table reports the published
reference, the number of patient analyzed in each publication, the number of mutation
detected (shown in brackets) in each publication for Sporadic (S-PD), Familiar (F-PD), and
mixed population (M-PD= S-PD+ F-PD). Box 1 shows data related to variant Asp620Asn
of VPS35; Box 2 shows data related to other variants of VPS35; Box 3 shows data related
to variants of VPS26a and VPS29. Each box reports in bold style: (i) the total number of
patients analyzed for each population, (ii) the number of variants identified (in bracket), and
(iii) the prevalence of each variant expressed as percentage of the population analyzed.
Nr, not reported %, percentage.
2014; Gagliardi et al., 2014). These studies analyzed a total of 7174
PD patients, 2800 with F-PD and 4374 with S-PD. Data were
obtained only for the most common mutation p.Asp620Asn,
which was detected in 1 sporadic (1/4374, 0.023%) and 8
familial (8/2800, 0.286%) patients (Table 1). When considering
the prevalence of F-PD compared with M-PD, the prevalence of
p.Asp620Asn calculated in a pure F-PD population increases up
to 10-fold compared with M-PD (two-tailed P = 0.0032).
Assuming the prevalence of rare VPS mutations from M-PD
studies (0.105%) as due to F-PD, the prevalence of all VPS35
variants in F-PD (both p.Asp620Asn and all rare variants) is
0.391% (0.286% of p.Asp620Asn in F-PD + 0.105 % or rare
variants in M-PD).
This is in line with what reported by Deng et al. (2013), who
considered VPS35 as the secondmost frequent cause of late-onset
F-PD (age at onset > 50 years), after LRRK2 mutations.
VARIANTS IN THE CARGO BINDING
TRIMERIC SUBCOMPLEX OF THE
RETROMER
Given the pathogenic effects of VPS35 mutations, other studies
aimed to establish the potential contribution to PD of other
VPS genes encoding for trimeric sub-complex of retromer.
Genetic screening on the whole VPS26a, VPS26b, and VPS29
genes have identified other VPS mutations which may produce
pathogenic effects both in PD and atypical parkinsonisms, such
as PSP (Progressive Supranuclear Palsy), MSA (Multiple system
atrophy), and Lewy body dementia (LBD) (Koschmidder et al.,
2014; Shannon et al., 2014; Gustavsson et al., 2015). These studies
considered S-PD and F-PD as M-PD, and they reported the
occurrence/absence of the disease only in the families of the
carriers.
When considering only those variants which are very likely to
produce deleterious effect, five mutations need to be considered
in VPS26a, one in VPS29, while no potentially pathogenic
variants are described so far in VPS26b. In depth analysis is
required to rule out definitely the pathogenic role of VPS26b
variants. In fact, such a lack of deleterious effects would
be unexpected when considering that VPS26b compete with
VPS26A for a single-binding site on VPS35 (Bugarcic et al.,
2011). All variants detected so far in VPS26a are placed outside
the VPS35 binding site (amino acids 235–246), being unlikely
to affect interactions between subunits of VPS35. For instance
p.Lys93Glu (c.A277G) in exon 4 is placed in a highly conserved
region of the VPS26a N-domain (amino acids 6-148), which
binds the receptor and promotes its internalization (Shi et al.,
2006). Although no functional studies have been reported, this
mutation may affect the binding to protein cargoes (Gustavsson
et al., 2015). This mutation has been identified in a Canadian
female (age at onset= 58) affected byMSA, and it was detected in
her sister who was also affected by MSA (Gustavsson et al., 2015).
Another case-control analysis identified this variant in a proband
with F-PD (age at onset = 56) and in two non-affected siblings
of her, suggesting an incomplete penetrance or an uncertain
Frontiers in Neuroscience | www.frontiersin.org 3 November 2016 | Volume 10 | Article 532
Gambardella et al. VPS Mutations, Retromers and PD
pathogenic effect (Shannon et al., 2014). Therefore, p.Lys93Glu
has been identified in sporadic and atypical PD patients.
Variation of codon 112 has been reported in two independent
analyses. A mutation p.Met112Ile, caused by a substitution in the
last nucleotide of the codon (c.336G>C) was reported in a S-
PD (Koschmidder et al., 2014), while p.Met112Val (c.334 A>G)
was identified in a patient with atypical PD (Gustavsson et al.,
2015). Similarly to aminoacid Lys93, Met112 takes place on an
external protein domain, and it may impair the interaction of
VPS26a with other retromer proteins (Gustavsson et al., 2015).
Interestingly, this variant was predicted to be benign by four of
the five in silico prediction software being tested, and its effects
remain to be evaluated in other PD patients (Koschmidder et al.,
2014; Gustavsson et al., 2015).
Other variants are placed in exon 9. For instance, p.Lys297X
has been identified in a Chamorro patient from Guam with
sporadic PSP (Gustavsson et al., 2015), while p.Pro316Ser has
been detected in a patient with S-PD, but even this mutation was
predicted to be a benign variant by in silico analysis. The effects of
exon 9 mutations on retromer functions are currently unknown
(Koschmidder et al., 2014).
In the VPS29 gene, variant p.Asn72His was identified in one
proband with PD (age at onset= 70). Even this variant, predicted
to be neutral, is placed outside the VPS35 binding site of VPS29
and it is unlikely to affect its binding to VPS35 (Shannon et al.,
2014).
Taken together, all VPS studies (except VPS35) identified 4
variants in M-PD (4/2547, 0.157%, Table 1), and 3 variants in
atypical PD (3/229, 1.31%), confirming the relevance of genetic
analysis of the trimeric sub-complex of the retromer both in PD
and atypical parkinsonism.
Cumulative prevalence of variants in all VPS genes in M-PD
is 0.377% (0.220% of all VPS35 variants in M-PD+ 0.157% of all
VPS26a, VPS26b, VPS29 variants in M-PD).
When considering the prevalence of mutations in VPS26a,
VPS26b, and VPS29 (0.157%) as calculated only from mixed
population (M-PD) studies, this corresponds to 0.157%.
When arbitrarily including these mutations as part of F-
PD, the prevalence of all VPS genes variants in F-PD rises
up to 0.548% (0.391% of all VPS35 variants in F-PD +
0.157 % of VPS26a, VPS26b, and VPS29 variants in M-PD;
Table 1).
VPS AND NEUROBIOLOGY OF PD
The re-appraisal of the prevalence of VPS genetic alterations,
apart from re-defining the relevance of this class of mutations in
causing F-PD, is helpful to analyze the potential dysfunctions of
VPS in producing sporadic PD. In fact, the process of disclosing
genetic determinants of PD provides molecular markers which
often are shared by all (genetic and sporadic) PD cases. The
proof of principle is represented by the case of alpha synuclein,
which is responsible for rare F-PD but it is found to be altered at
molecular level in almost all PD phenotypes where it represents
the hallmark of proteinaceous aggregates known as Lewy Bodies
(Spillantini et al., 1997). In fact, alpha synuclein provided the
basis to unravel the general mechanisms of action of misfolded
proteins, which is relevant to interpret the disease course both
in familial and sporadic PD (Fornai et al., 2005a,b,c, 2006,
2008; Giorgi et al., 2006; Iacovelli et al., 2006; Mauceli et al.,
2006; Lazzeri et al., 2007; Ferrucci et al., 2008). In keeping
with this, the role of VPS is key in releasing protein-enriched
exosomes. This is critical to understand disease propagation
through synaptically connected regions along the whole CNS.
In this way, VPS mutations may be a pivot to understand
cell-to-cell transmission of protein cargoes through exosomes
(Danzer et al., 2012; Poehler et al., 2014; Tsunemi et al., 2014;
Emmanouilidou and Vekrellis, 2016; Lööv et al., 2016; Figure 1).
Thus, an in depth analysis of VPS alterations is expected to
disclose the anatomical basis of disease progression as recently
described (Hawkes et al., 2010; Del Tredici and Braak, 2013;
Holmqvist et al., 2014; Garcia-Esparcia et al., 2015; Lamberts
et al., 2015). Within this scenario one should consider that VPS is
involved in clearing misfolded proteins as well as a variety of cell
material within exosomes and diffusible retromers (Figure 1). A
knowledge of cell pathology produced by specific variants of VPS
is relevant to describe the molecular mechanisms involved in
abnormal cell-to-cell transmission. In keeping with this, it should
be considered that VPS35 mutations represent an autosomal
dominant genetic disorder. This suggests a pathological gain
of function. Thus, one may hypothesize that an overactive
exosome may increase retromers availability, thus contributing
to the spreading of pathological cargoes along the CNS. If this
hypothesis is correct one should expect that decreased retromer
activity may exert a protective role. Unexpectedly, this is just
the opposite of what has been recently indicated by Tang et al.
(2015b), who demonstrated that, the loss of retromer activity
leads to the loss of dopamine-containing neurons. Thus, it is
likely that mutations leading to PD impair retromer activity,
rather than providing an enhancement of retromer function. The
dominant nature of these mutations imply that the activity of
retromers needs to be highly preserved in order to keep cell
homeostasis. Since the main function of retromers consists in
transporting cell material from the plasma membrane to the
trans Golgi network and back again, it is likely that even a
slight disruption of this trafficking may impair cell survival.
In fact, when assayed in the presence of an excess of alpha
synuclein, in alpha synuclein transgenic mice, the concomitant
over-expression of native VPS35 counteracts alpha-synuclein-
dependent toxicity (Dhungel et al., 2015). In order to produce
its beneficial effects VPS35 needs to be structurally intact since
the up-regulation of mutant VPS35 worsens the neurotoxic
effects produced by alpha synuclein (Dhungel et al., 2015). In
light of these findings the effective activity of VPS appears
to be critical to promote retromer function, thus providing
a key step in the removal of toxic substrates (Wang et al.,
2016; Figure 1). This is confirmed by Sowada et al. (2016) who
showed protection from copper toxicity in yeast over-expressing
VPS35, while copper and alpha-synuclein toxicity is enhanced
in the same cells upon VPS35 dysfunction produced by VPS35
mutations. The natural function of VPS35 is bound to the
PARK2 gene described as parkin (Kitada et al., 1998). In fact,
despite multiple roles exerted by parkin as a E3 ubiquitin ligase
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FIGURE 1 | VPS mutations and retromer dysfunction. This cartoon reports the most relevant effects of VPS dysfunction on the molecular mechanisms involved in
cellular trafficking. Mutations (nr.1) occurring in any of the Vacuolar Protein Sorting components of the retromer (VPS35, VPS26, and VPS29) may lead to increased
levels of misfolded proteins, thereby causing abnormal sorting and trafficking. In an attempt to get rid of misfolded proteins, the routine trafficking may shift from
endosomes and trans-Golgi network (TGN) to the cell membrane to produce the release of aberrant cargoes. Diffusible retromers may be key in neurodegenerative
disorders, posing this unconventional mechanism of cell-to-cell communication as a cause of disease spreading. Retromer dysfunction may also derive from
mutations (nr.2) impairing the retrograde transport of cation-independent mannose-6-phosphate receptor (CIM6PR), which in turn becomes unable to bind cathepsin
D and other proteases to the TGN, to be delivered to the endosome (Miura et al., 2014). Since cathepsin D is an endosome–lysosome protease which is crucial for
degrading α-synuclein, this may explain the occurrence of α-synuclein accumulation also in the course of retromer-related PD. The relevance of the
endosomal/retromer/exosome compartment in PD is supported by the interaction of VPS35 with parkin by promoting Rab7 ubiquitination. In fact, Parkin mutations
(nr.3) are associated with retromer dysfunctions (Song et al., 2016). In line with consistent finding on mitochondrial alterations in PD, VPS35 was shown to modulate
mitochondrial integrity and mitochondrial turnover (Tang et al., 2015b; Wang et al., 2016).
(modulating both proteasome and autophagy activity), it seems
that the most relevant effects are produced by its interaction
with the endosomal compartment. Parkin was recently shown
to regulate endosomal activity just based on its interaction with
VPS35 (Song et al., 2016). These data strongly suggest that
endocytic compartment is likely to be highly relevant in PD.
This concept does not rule out previous findings showing both
proteasome and autophagosome dysfunction. In fact all these
compartments eventually merge to produce an ultimate organelle
which fuses with lysosomes (Lenzi et al., 2016). The specific fate
of endosomes is related to the chance that, despite routinely
shuttling toward the trans Golgi network, this compartment
may be delivered to the cell membrane to be released. This is
effectively commented by Zhang and Schekman (2013) under
the title “unconventional secretions, unconventional solutions.”
Thus, we may consider that a dysfunction in the VPS complex
shifts the routine trafficking from endosomes and trans Golgi
network to the cell membrane to produce the release of toxic
cargoes (Figure 1). In keeping with this hypothesis we may argue
that a mutation in the VPS complex produces an abnormal
cargoes release since the natural intracellular trafficking is no
longer able to clean the cells from overwhelming retromers. This
may explain why Song et al. (2016) described the occurrence
of abnormal endosomes within parkin deficient cells where the
endosomal cargoes were delivered to the extracellular space to be
released. The emphasis which derives from recent findings on the
pivotal role of the endosomal/retromer/exosome compartment
in PD pathogenesis remains to be clearly balanced. For instance,
recent studies demonstrate that a mutation of VPS35 alters
the mitochondrial turnover (Tang et al., 2015a,b; Wang et al.,
2016). These findings pose uncertain outcomes, which remain
difficult to explain simply based on the current knowledge on
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the endosomal compartment. Understanding the significance
of various mutations of VPS is key to dissect the site-specific
relevance of each specific VPS isoform and it may help to
understand why certain VPS mutations are associated with PD
while others are linked to AD or may produce mixed disease
phenotypes known as atypical PD.
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